BioNxt Solutions (XTER:BXT) Total Noninterest Expense

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:BXT BioNxt Solutions Inc XTER:BXT
31 GF Score
Price €0.18
GF Value €0.15
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is BioNxt Solutions Total Noninterest Expense?

Total Noninterest Expense only applies to banks.

XTER:BXT
31GF Score
BioNxt Solutions Inc XTER:BXT
Total Noninterest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioNxt Solutions (XTER:BXT) Overvalued in 2026?

Based on GuruFocus' analysis, BioNxt Solutions stock appears to be overvalued. The current stock price of €0.18 is trading 20% above its estimated GF Value™ of €0.15. GuruFocus considers BioNxt Solutions to be Modestly Overvalued.

Key valuation signals for XTER:BXT:

  • Total Noninterest Expense:
  • GF Value™: €0.15 vs. price of €0.18 (20% above fair value)
  • GF Score™: 31/100 with 4 warning signs

No single metric tells the full story. See the XTER:BXT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioNxt Solutions Business Description

Address 1928 Linden Road, Vancouver, BC, CAN, V6M 1E7
BioNxt Solutions Inc is is a bioscience innovator focused on next-generation drug delivery systems. With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, focused on European markets. The company is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes. Its pipeline includes BNT23001, BNT23002, BNT24002, BNT24003, BNT24004. Its geographic areas are Austria, Germany, Switzerland regions.
31GF Score

Get the complete analysis for XTER:BXT

Total Noninterest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.18
Price
€0.15
GF Value